DHEA
DHEA Suppositories- A Recent Study
Effect of intravaginal dehydroepiandrosterone (prasterone) on libido and sexual dysfunction in postmenopausal women.
According to the study, since the ovules (suppositories) used yielded different mg DHEA per supp…..
0.25% (3.25MG DHEA), 0.5% (6.5MG DHEA), 1.0% (13MG DHEA) PER OVULE….
3 SYMPTOMS were reported:
Results after 12 weeks of using DHEA suppositories:
Score of the sexual domain of the MENQOL
Avoiding intimacy scores
Vaginal Dryness
Sexual desire improvement
Arousal-lubrication
Orgasm (increases from baseline)
Conclusions:
The new knowledge gained about intrcrinology in women clearly indicated that the appearance of symptoms of vaginal atrophy in postmenopausal women is due to a lack of DHEA and/or insufficient transformation of this precursor into active androgens and/or estrogens in the vagina. Most interestingly, the present data show that in addition to very rapidly and efficiently correcting the symptoms and signs of vaginal atrophy, the local application of DHEA in the vagina has a marked influence on all aspects of sexual function, this indicating the role of an androgenic component of DHEA transformation on vaginal health, which permits improvement in desire, arousal, orgasm, and pleasure.
The present beneficial effects of intravaginal DHEA on sexual dysfunction in women, including orgasm, can be compared to the success of oral therapy for erectile dysfunction in men. A marked difference, however, between the treatment of erectile dysfunction in men and the present treatment of sexual dysfunction in women is that local treatment with DHEA achieves its beneficial effects without significant systemic exposure to a drug, thus avoiding potential systemic risks.”
DHEA vaginal suppositories (ovules) 3.25mg each
Directions for use: Insert 1 suppository into vagina every night for 12 weeks, then 2-3 times per week.
References:
Labrie F, Archer D, Bouchard C, et. al. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause: The Journal of The North American Menopause Society. 2009:16(5);923-31.
According to the study, since the ovules (suppositories) used yielded different mg DHEA per supp…..
0.25% (3.25MG DHEA), 0.5% (6.5MG DHEA), 1.0% (13MG DHEA) PER OVULE….
3 SYMPTOMS were reported:
- 64% vaginal pain at sexual activity
- 28% vaginal dryness
- 8% irritation and itching
Results after 12 weeks of using DHEA suppositories:
Score of the sexual domain of the MENQOL
- 0.25% DHEA decreased by 2.85 (54% improvement)
- 0.5% dec by 1.92 (43% improvement)
- 1.0% dec by 2.50 (53% improvement)
- Placebo- 32% improvement
Avoiding intimacy scores
- 0.25% DHEA decreased scores by 46%
- 0.5%- decreased by 53%
- 1.0%- decreased by 51%
- Placebo- decreased by 26%
Vaginal Dryness
- 0.25% DHEA resulted in 58% decrease in severity score
- 0.5%- 53% decrease in severity
- 1.0%- 57% decreases in severity
- Placebo- decreased by 28%
Sexual desire improvement
- 0.25% DHEA showed 55% improvement
- 0.5%- 32% improvement
- 1.0%- improved by 49%
- Placebo- 23% improvement
Arousal-lubrication
- 0.25% DHEA- lubrication improved by 169%
- 0.5%- improved by 162%
- 1.0%- 139% improvement
- Placebo- 49% improvement
Orgasm (increases from baseline)
- 0.25% DHEA- patients reported 65% increase from baseline
- 0.5% DHEA- 56% increase
- 1.0%- 75% increase
- Placebo- 31% increase from baseline
Conclusions:
The new knowledge gained about intrcrinology in women clearly indicated that the appearance of symptoms of vaginal atrophy in postmenopausal women is due to a lack of DHEA and/or insufficient transformation of this precursor into active androgens and/or estrogens in the vagina. Most interestingly, the present data show that in addition to very rapidly and efficiently correcting the symptoms and signs of vaginal atrophy, the local application of DHEA in the vagina has a marked influence on all aspects of sexual function, this indicating the role of an androgenic component of DHEA transformation on vaginal health, which permits improvement in desire, arousal, orgasm, and pleasure.
The present beneficial effects of intravaginal DHEA on sexual dysfunction in women, including orgasm, can be compared to the success of oral therapy for erectile dysfunction in men. A marked difference, however, between the treatment of erectile dysfunction in men and the present treatment of sexual dysfunction in women is that local treatment with DHEA achieves its beneficial effects without significant systemic exposure to a drug, thus avoiding potential systemic risks.”
DHEA vaginal suppositories (ovules) 3.25mg each
Directions for use: Insert 1 suppository into vagina every night for 12 weeks, then 2-3 times per week.
References:
Labrie F, Archer D, Bouchard C, et. al. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause: The Journal of The North American Menopause Society. 2009:16(5);923-31.